PHOENIX--(BUSINESS WIRE)--Zila, Inc. (NASDAQ:ZILAD) today announced encouraging preliminary results of an in vivo animal study which showed evidence of photodestruction of premalignant lesions and squamous cell carcinoma when treated with Zila’s patented pharmaceutical grade toluidine blue, both a diagnostic adjuvant and a photosensitizer for DMBA-induced precancers and cancers in the hamster cheek pouch model. Squamous cell carcinoma is the most common form of oral, cervical and, esophageal cancers.
